Press Releases
Site - Investor Relations
“These results demonstrate that PeDAL works with real world drug compounds and tumor samples,”
Discovery 21 tested PeDAL’s ability to make drug response predictions, starting with an experimental space of 175 FDA-approved cancer drugs and tumor samples from 130 ovarian cancers. “POAI has a database with drug response results for over 150,000 tumor samples in over 137 tumor types,” said
The completion of Discovery 21, and its subsequent validation, creates a path for
About
Investor Relations Contact:
(404) 995-6671
kpinder@landoncapital.net
Forward-Looking Statements: Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect the company’s current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about its operations and the investments made. All statements, other than statements of historical facts, included in this press release regarding the company strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The Company’s actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, risks that
Source: Predictive Oncology Inc.